Global Genomics Personalized Health Market by Test Type (Oncology Testing, Orphan Disease Testing, Autoimmune Disease Testing, Infectious Disease Testing, Obstetrics Testing), by Technology (Microarray, NGS platforms, RT-PCR, Genetic Analyzers), by End User (Academic Research Institutes, Diagnostic Centers) and Region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa), Forecast To 2028
Up Market Research published a new report titled “Genomics Personalized Health Market research report which is segmented by Test Type (Oncology Testing, Orphan Disease Testing, Autoimmune Disease Testing, Infectious Disease Testing, Obstetrics Testing), by Technology (Microarray, NGS platforms, RT-PCR, Genetic Analyzers), by End User (Academic Research Institutes, Diagnostic Centers), By Players/Companies F. Hoffmann-La Roche AG, Interleukin Genetics Inc., DNA Genotek Inc., Genetic Technologies Limited, Eastern Biotech and Life Sciences, Biome Inc., INVITAE Corporation, Thermo Fisher Scientific Inc., QIAGEN, Bio-Rad Laboratories Inc., XCode Life Sciences Private Limited., Lonza Group, Illumina Inc.”. As per the study the market is expected to grow at a CAGR of XX% in the forecast period.
Report Scope
| Report Attributes | Report Details |
| Report Title | Genomics Personalized Health Market Research Report |
| By Test Type | Oncology Testing, Orphan Disease Testing, Autoimmune Disease Testing, Infectious Disease Testing, Obstetrics Testing |
| By Technology | Microarray, NGS platforms, RT-PCR, Genetic Analyzers |
| By End User | Academic Research Institutes, Diagnostic Centers |
| By Companies | F. Hoffmann-La Roche AG, Interleukin Genetics Inc., DNA Genotek Inc., Genetic Technologies Limited, Eastern Biotech and Life Sciences, Biome Inc., INVITAE Corporation, Thermo Fisher Scientific Inc., QIAGEN, Bio-Rad Laboratories Inc., XCode Life Sciences Private Limited., Lonza Group, Illumina Inc. |
| Regions Covered | North America, Europe, APAC, Latin America, MEA |
| Base Year | 2020 |
| Historical Year | 2018 to 2019 (Data from 2010 can be provided as per availability) |
| Forecast Year | 2028 |
| Number of Pages | 211 |
| Number of Tables & Figures | 148 |
| Customization Available | Yes, the report can be customized as per your need. |
The report covers comprehensive data on emerging trends, market drivers, growth opportunities, and restraints that can change the market dynamics of the industry. It provides an in-depth analysis of the market segments which include products, applications, and competitor analysis.
Global Genomics Personalized Health Market Report Segments:
The market is segmented by Test Type (Oncology Testing, Orphan Disease Testing, Autoimmune Disease Testing, Infectious Disease Testing, Obstetrics Testing), by Technology (Microarray, NGS platforms, RT-PCR, Genetic Analyzers), by End User (Academic Research Institutes, Diagnostic Centers).
Genomics Personalized Health Market research report delivers a close watch on leading competitors with strategic analysis, micro and macro market trend and scenarios, pricing analysis and a holistic overview of the market situations in the forecast period. It is a professional and a detailed report focusing on primary and secondary drivers, market share, leading segments and geographical analysis. Further, key players, major collaborations, merger & acquisitions along with trending innovation and business policies are reviewed in the report.
Key Benefits for Industry Participants & Stakeholders:
- Industry drivers, restraints, and opportunities covered in the study
- Neutral perspective on the market performance
- Recent industry trends and developments
- Competitive landscape & strategies of key players
- Potential & niche segments and regions exhibiting promising growth covered
- Historical, current, and projected market size, in terms of value
- In-depth analysis of the Genomics Personalized Health Market
Overview of the regional outlook of the Genomics Personalized Health Market:
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa (MEA). North America region is further bifurcated into countries such as U.S., and Canada. The Europe region is further categorized into U.K., France, Germany, Italy, Spain, Russia, and Rest of Europe. Asia Pacific is further segmented into China, Japan, South Korea, India, Australia, South East Asia, and Rest of Asia Pacific. Latin America region is further segmented into Brazil, Mexico, and Rest of Latin America, and the MEA region is further divided into GCC, Turkey, South Africa, and Rest of MEA.
Highlights of The Genomics Personalized Health Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of Genomics Personalized Health Market.
- Historical data and forecast.
- Estimations for the forecast period 2028.
- Developments and trends in the market.
1. Oncology Testing
2. Orphan Disease Testing
3. Autoimmune Disease Testing
4. Infectious Disease Testing
5. Obstetrics Testing
7. By Technology:1. Microarray
2. NGS platforms
3. RT-PCR
4. Genetic Analyzers
8. By End User:1. Academic Research Institutes
2. Diagnostic Centers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Genomics Personalized Health Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2028.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
Reasons to Purchase the Genomics Personalized Health Market Report:
- The report includes a plethora of information such as market dynamics scenario and opportunities during the forecast period
- Segments and sub-segments include quantitative, qualitative, value (USD Million,) and volume (Units Million) data.
- Regional, sub-regional, and country level data includes the demand and supply forces along with their influence on the market.
- The competitive landscape comprises share of key players, new developments, and strategies in the last three years.
- Comprehensive companies offering products, relevant financial information, recent developments, SWOT analysis, and strategies by these players.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Genomics Personalized Health Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Genomics Personalized Health Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Genomics Personalized Health Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Genomics Personalized Health Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Genomics Personalized Health Market Size & Forecast, 2018-2028
4.5.1 Genomics Personalized Health Market Size and Y-o-Y Growth
4.5.2 Genomics Personalized Health Market Absolute $ Opportunity
Chapter 5 Global Genomics Personalized Health Market Analysis and Forecast by Test Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Test Type
5.1.2 Basis Point Share (BPS) Analysis by Test Type
5.1.3 Absolute $ Opportunity Assessment by Test Type
5.2 Genomics Personalized Health Market Size Forecast by Test Type
5.2.1 Oncology Testing
5.2.2 Orphan Disease Testing
5.2.3 Autoimmune Disease Testing
5.2.4 Infectious Disease Testing
5.2.5 Obstetrics Testing
5.3 Market Attractiveness Analysis by Test Type
Chapter 6 Global Genomics Personalized Health Market Analysis and Forecast by Technology
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Technology
6.1.2 Basis Point Share (BPS) Analysis by Technology
6.1.3 Absolute $ Opportunity Assessment by Technology
6.2 Genomics Personalized Health Market Size Forecast by Technology
6.2.1 Microarray
6.2.2 NGS platforms
6.2.3 RT-PCR
6.2.4 Genetic Analyzers
6.3 Market Attractiveness Analysis by Technology
Chapter 7 Global Genomics Personalized Health Market Analysis and Forecast by End User
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by End User
7.1.2 Basis Point Share (BPS) Analysis by End User
7.1.3 Absolute $ Opportunity Assessment by End User
7.2 Genomics Personalized Health Market Size Forecast by End User
7.2.1 Academic Research Institutes
7.2.2 Diagnostic Centers
7.3 Market Attractiveness Analysis by End User
Chapter 8 Global Genomics Personalized Health Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Genomics Personalized Health Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Genomics Personalized Health Analysis and Forecast
10.1 Introduction
10.2 North America Genomics Personalized Health Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Genomics Personalized Health Market Size Forecast by Test Type
10.6.1 Oncology Testing
10.6.2 Orphan Disease Testing
10.6.3 Autoimmune Disease Testing
10.6.4 Infectious Disease Testing
10.6.5 Obstetrics Testing
10.7 Basis Point Share (BPS) Analysis by Test Type
10.8 Absolute $ Opportunity Assessment by Test Type
10.9 Market Attractiveness Analysis by Test Type
10.10 North America Genomics Personalized Health Market Size Forecast by Technology
10.10.1 Microarray
10.10.2 NGS platforms
10.10.3 RT-PCR
10.10.4 Genetic Analyzers
10.11 Basis Point Share (BPS) Analysis by Technology
10.12 Absolute $ Opportunity Assessment by Technology
10.13 Market Attractiveness Analysis by Technology
10.14 North America Genomics Personalized Health Market Size Forecast by End User
10.14.1 Academic Research Institutes
10.14.2 Diagnostic Centers
10.15 Basis Point Share (BPS) Analysis by End User
10.16 Absolute $ Opportunity Assessment by End User
10.17 Market Attractiveness Analysis by End User
Chapter 11 Europe Genomics Personalized Health Analysis and Forecast
11.1 Introduction
11.2 Europe Genomics Personalized Health Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Genomics Personalized Health Market Size Forecast by Test Type
11.6.1 Oncology Testing
11.6.2 Orphan Disease Testing
11.6.3 Autoimmune Disease Testing
11.6.4 Infectious Disease Testing
11.6.5 Obstetrics Testing
11.7 Basis Point Share (BPS) Analysis by Test Type
11.8 Absolute $ Opportunity Assessment by Test Type
11.9 Market Attractiveness Analysis by Test Type
11.10 Europe Genomics Personalized Health Market Size Forecast by Technology
11.10.1 Microarray
11.10.2 NGS platforms
11.10.3 RT-PCR
11.10.4 Genetic Analyzers
11.11 Basis Point Share (BPS) Analysis by Technology
11.12 Absolute $ Opportunity Assessment by Technology
11.13 Market Attractiveness Analysis by Technology
11.14 Europe Genomics Personalized Health Market Size Forecast by End User
11.14.1 Academic Research Institutes
11.14.2 Diagnostic Centers
11.15 Basis Point Share (BPS) Analysis by End User
11.16 Absolute $ Opportunity Assessment by End User
11.17 Market Attractiveness Analysis by End User
Chapter 12 Asia Pacific Genomics Personalized Health Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Genomics Personalized Health Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Genomics Personalized Health Market Size Forecast by Test Type
12.6.1 Oncology Testing
12.6.2 Orphan Disease Testing
12.6.3 Autoimmune Disease Testing
12.6.4 Infectious Disease Testing
12.6.5 Obstetrics Testing
12.7 Basis Point Share (BPS) Analysis by Test Type
12.8 Absolute $ Opportunity Assessment by Test Type
12.9 Market Attractiveness Analysis by Test Type
12.10 Asia Pacific Genomics Personalized Health Market Size Forecast by Technology
12.10.1 Microarray
12.10.2 NGS platforms
12.10.3 RT-PCR
12.10.4 Genetic Analyzers
12.11 Basis Point Share (BPS) Analysis by Technology
12.12 Absolute $ Opportunity Assessment by Technology
12.13 Market Attractiveness Analysis by Technology
12.14 Asia Pacific Genomics Personalized Health Market Size Forecast by End User
12.14.1 Academic Research Institutes
12.14.2 Diagnostic Centers
12.15 Basis Point Share (BPS) Analysis by End User
12.16 Absolute $ Opportunity Assessment by End User
12.17 Market Attractiveness Analysis by End User
Chapter 13 Latin America Genomics Personalized Health Analysis and Forecast
13.1 Introduction
13.2 Latin America Genomics Personalized Health Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Genomics Personalized Health Market Size Forecast by Test Type
13.6.1 Oncology Testing
13.6.2 Orphan Disease Testing
13.6.3 Autoimmune Disease Testing
13.6.4 Infectious Disease Testing
13.6.5 Obstetrics Testing
13.7 Basis Point Share (BPS) Analysis by Test Type
13.8 Absolute $ Opportunity Assessment by Test Type
13.9 Market Attractiveness Analysis by Test Type
13.10 Latin America Genomics Personalized Health Market Size Forecast by Technology
13.10.1 Microarray
13.10.2 NGS platforms
13.10.3 RT-PCR
13.10.4 Genetic Analyzers
13.11 Basis Point Share (BPS) Analysis by Technology
13.12 Absolute $ Opportunity Assessment by Technology
13.13 Market Attractiveness Analysis by Technology
13.14 Latin America Genomics Personalized Health Market Size Forecast by End User
13.14.1 Academic Research Institutes
13.14.2 Diagnostic Centers
13.15 Basis Point Share (BPS) Analysis by End User
13.16 Absolute $ Opportunity Assessment by End User
13.17 Market Attractiveness Analysis by End User
Chapter 14 Middle East & Africa (MEA) Genomics Personalized Health Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Genomics Personalized Health Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Genomics Personalized Health Market Size Forecast by Test Type
14.6.1 Oncology Testing
14.6.2 Orphan Disease Testing
14.6.3 Autoimmune Disease Testing
14.6.4 Infectious Disease Testing
14.6.5 Obstetrics Testing
14.7 Basis Point Share (BPS) Analysis by Test Type
14.8 Absolute $ Opportunity Assessment by Test Type
14.9 Market Attractiveness Analysis by Test Type
14.10 Middle East & Africa (MEA) Genomics Personalized Health Market Size Forecast by Technology
14.10.1 Microarray
14.10.2 NGS platforms
14.10.3 RT-PCR
14.10.4 Genetic Analyzers
14.11 Basis Point Share (BPS) Analysis by Technology
14.12 Absolute $ Opportunity Assessment by Technology
14.13 Market Attractiveness Analysis by Technology
14.14 Middle East & Africa (MEA) Genomics Personalized Health Market Size Forecast by End User
14.14.1 Academic Research Institutes
14.14.2 Diagnostic Centers
14.15 Basis Point Share (BPS) Analysis by End User
14.16 Absolute $ Opportunity Assessment by End User
14.17 Market Attractiveness Analysis by End User
Chapter 15 Competition Landscape
15.1 Genomics Personalized Health Market: Competitive Dashboard
15.2 Global Genomics Personalized Health Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 F. Hoffmann-La Roche AG
15.3.2 Interleukin Genetics Inc.
15.3.3 DNA Genotek Inc.
15.3.4 Genetic Technologies Limited
15.3.5 Eastern Biotech and Life Sciences
15.3.6 Biome Inc.
15.3.7 INVITAE Corporation
15.3.8 Thermo Fisher Scientific Inc.
15.3.9 QIAGEN
15.3.10 Bio-Rad Laboratories Inc.
15.3.11 XCode Life Sciences Private Limited.
15.3.12 Lonza Group
15.3.13 Illumina Inc.
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Genomics Personalized Health Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Genomics Personalized Health Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Genomics Personalized Health Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Genomics Personalized Health Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Genomics Personalized Health Market Size & Forecast, 2018-2028
4.5.1 Genomics Personalized Health Market Size and Y-o-Y Growth
4.5.2 Genomics Personalized Health Market Absolute $ Opportunity
Chapter 5 Global Genomics Personalized Health Market Analysis and Forecast by Test Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Test Type
5.1.2 Basis Point Share (BPS) Analysis by Test Type
5.1.3 Absolute $ Opportunity Assessment by Test Type
5.2 Genomics Personalized Health Market Size Forecast by Test Type
5.2.1 Oncology Testing
5.2.2 Orphan Disease Testing
5.2.3 Autoimmune Disease Testing
5.2.4 Infectious Disease Testing
5.2.5 Obstetrics Testing
5.3 Market Attractiveness Analysis by Test Type
Chapter 6 Global Genomics Personalized Health Market Analysis and Forecast by Technology
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Technology
6.1.2 Basis Point Share (BPS) Analysis by Technology
6.1.3 Absolute $ Opportunity Assessment by Technology
6.2 Genomics Personalized Health Market Size Forecast by Technology
6.2.1 Microarray
6.2.2 NGS platforms
6.2.3 RT-PCR
6.2.4 Genetic Analyzers
6.3 Market Attractiveness Analysis by Technology
Chapter 7 Global Genomics Personalized Health Market Analysis and Forecast by End User
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by End User
7.1.2 Basis Point Share (BPS) Analysis by End User
7.1.3 Absolute $ Opportunity Assessment by End User
7.2 Genomics Personalized Health Market Size Forecast by End User
7.2.1 Academic Research Institutes
7.2.2 Diagnostic Centers
7.3 Market Attractiveness Analysis by End User
Chapter 8 Global Genomics Personalized Health Market Analysis and Forecast by Region
8.1 Introduction
8.1.1 Key Market Trends & Growth Opportunities by Region
8.1.2 Basis Point Share (BPS) Analysis by Region
8.1.3 Absolute $ Opportunity Assessment by Region
8.2 Genomics Personalized Health Market Size Forecast by Region
8.2.1 North America
8.2.2 Europe
8.2.3 Asia Pacific
8.2.4 Latin America
8.2.5 Middle East & Africa (MEA)
8.3 Market Attractiveness Analysis by Region
Chapter 9 Coronavirus Disease (COVID-19) Impact
9.1 Introduction
9.2 Current & Future Impact Analysis
9.3 Economic Impact Analysis
9.4 Government Policies
9.5 Investment Scenario
Chapter 10 North America Genomics Personalized Health Analysis and Forecast
10.1 Introduction
10.2 North America Genomics Personalized Health Market Size Forecast by Country
10.2.1 U.S.
10.2.2 Canada
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 North America Genomics Personalized Health Market Size Forecast by Test Type
10.6.1 Oncology Testing
10.6.2 Orphan Disease Testing
10.6.3 Autoimmune Disease Testing
10.6.4 Infectious Disease Testing
10.6.5 Obstetrics Testing
10.7 Basis Point Share (BPS) Analysis by Test Type
10.8 Absolute $ Opportunity Assessment by Test Type
10.9 Market Attractiveness Analysis by Test Type
10.10 North America Genomics Personalized Health Market Size Forecast by Technology
10.10.1 Microarray
10.10.2 NGS platforms
10.10.3 RT-PCR
10.10.4 Genetic Analyzers
10.11 Basis Point Share (BPS) Analysis by Technology
10.12 Absolute $ Opportunity Assessment by Technology
10.13 Market Attractiveness Analysis by Technology
10.14 North America Genomics Personalized Health Market Size Forecast by End User
10.14.1 Academic Research Institutes
10.14.2 Diagnostic Centers
10.15 Basis Point Share (BPS) Analysis by End User
10.16 Absolute $ Opportunity Assessment by End User
10.17 Market Attractiveness Analysis by End User
Chapter 11 Europe Genomics Personalized Health Analysis and Forecast
11.1 Introduction
11.2 Europe Genomics Personalized Health Market Size Forecast by Country
11.2.1 Germany
11.2.2 France
11.2.3 Italy
11.2.4 U.K.
11.2.5 Spain
11.2.6 Russia
11.2.7 Rest of Europe
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Europe Genomics Personalized Health Market Size Forecast by Test Type
11.6.1 Oncology Testing
11.6.2 Orphan Disease Testing
11.6.3 Autoimmune Disease Testing
11.6.4 Infectious Disease Testing
11.6.5 Obstetrics Testing
11.7 Basis Point Share (BPS) Analysis by Test Type
11.8 Absolute $ Opportunity Assessment by Test Type
11.9 Market Attractiveness Analysis by Test Type
11.10 Europe Genomics Personalized Health Market Size Forecast by Technology
11.10.1 Microarray
11.10.2 NGS platforms
11.10.3 RT-PCR
11.10.4 Genetic Analyzers
11.11 Basis Point Share (BPS) Analysis by Technology
11.12 Absolute $ Opportunity Assessment by Technology
11.13 Market Attractiveness Analysis by Technology
11.14 Europe Genomics Personalized Health Market Size Forecast by End User
11.14.1 Academic Research Institutes
11.14.2 Diagnostic Centers
11.15 Basis Point Share (BPS) Analysis by End User
11.16 Absolute $ Opportunity Assessment by End User
11.17 Market Attractiveness Analysis by End User
Chapter 12 Asia Pacific Genomics Personalized Health Analysis and Forecast
12.1 Introduction
12.2 Asia Pacific Genomics Personalized Health Market Size Forecast by Country
12.2.1 China
12.2.2 Japan
12.2.3 South Korea
12.2.4 India
12.2.5 Australia
12.2.6 South East Asia (SEA)
12.2.7 Rest of Asia Pacific (APAC)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Asia Pacific Genomics Personalized Health Market Size Forecast by Test Type
12.6.1 Oncology Testing
12.6.2 Orphan Disease Testing
12.6.3 Autoimmune Disease Testing
12.6.4 Infectious Disease Testing
12.6.5 Obstetrics Testing
12.7 Basis Point Share (BPS) Analysis by Test Type
12.8 Absolute $ Opportunity Assessment by Test Type
12.9 Market Attractiveness Analysis by Test Type
12.10 Asia Pacific Genomics Personalized Health Market Size Forecast by Technology
12.10.1 Microarray
12.10.2 NGS platforms
12.10.3 RT-PCR
12.10.4 Genetic Analyzers
12.11 Basis Point Share (BPS) Analysis by Technology
12.12 Absolute $ Opportunity Assessment by Technology
12.13 Market Attractiveness Analysis by Technology
12.14 Asia Pacific Genomics Personalized Health Market Size Forecast by End User
12.14.1 Academic Research Institutes
12.14.2 Diagnostic Centers
12.15 Basis Point Share (BPS) Analysis by End User
12.16 Absolute $ Opportunity Assessment by End User
12.17 Market Attractiveness Analysis by End User
Chapter 13 Latin America Genomics Personalized Health Analysis and Forecast
13.1 Introduction
13.2 Latin America Genomics Personalized Health Market Size Forecast by Country
13.2.1 Brazil
13.2.2 Mexico
13.2.3 Rest of Latin America (LATAM)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Latin America Genomics Personalized Health Market Size Forecast by Test Type
13.6.1 Oncology Testing
13.6.2 Orphan Disease Testing
13.6.3 Autoimmune Disease Testing
13.6.4 Infectious Disease Testing
13.6.5 Obstetrics Testing
13.7 Basis Point Share (BPS) Analysis by Test Type
13.8 Absolute $ Opportunity Assessment by Test Type
13.9 Market Attractiveness Analysis by Test Type
13.10 Latin America Genomics Personalized Health Market Size Forecast by Technology
13.10.1 Microarray
13.10.2 NGS platforms
13.10.3 RT-PCR
13.10.4 Genetic Analyzers
13.11 Basis Point Share (BPS) Analysis by Technology
13.12 Absolute $ Opportunity Assessment by Technology
13.13 Market Attractiveness Analysis by Technology
13.14 Latin America Genomics Personalized Health Market Size Forecast by End User
13.14.1 Academic Research Institutes
13.14.2 Diagnostic Centers
13.15 Basis Point Share (BPS) Analysis by End User
13.16 Absolute $ Opportunity Assessment by End User
13.17 Market Attractiveness Analysis by End User
Chapter 14 Middle East & Africa (MEA) Genomics Personalized Health Analysis and Forecast
14.1 Introduction
14.2 Middle East & Africa (MEA) Genomics Personalized Health Market Size Forecast by Country
14.2.1 Saudi Arabia
14.2.2 South Africa
14.2.3 UAE
14.2.4 Rest of Middle East & Africa (MEA)
14.3 Basis Point Share (BPS) Analysis by Country
14.4 Absolute $ Opportunity Assessment by Country
14.5 Market Attractiveness Analysis by Country
14.6 Middle East & Africa (MEA) Genomics Personalized Health Market Size Forecast by Test Type
14.6.1 Oncology Testing
14.6.2 Orphan Disease Testing
14.6.3 Autoimmune Disease Testing
14.6.4 Infectious Disease Testing
14.6.5 Obstetrics Testing
14.7 Basis Point Share (BPS) Analysis by Test Type
14.8 Absolute $ Opportunity Assessment by Test Type
14.9 Market Attractiveness Analysis by Test Type
14.10 Middle East & Africa (MEA) Genomics Personalized Health Market Size Forecast by Technology
14.10.1 Microarray
14.10.2 NGS platforms
14.10.3 RT-PCR
14.10.4 Genetic Analyzers
14.11 Basis Point Share (BPS) Analysis by Technology
14.12 Absolute $ Opportunity Assessment by Technology
14.13 Market Attractiveness Analysis by Technology
14.14 Middle East & Africa (MEA) Genomics Personalized Health Market Size Forecast by End User
14.14.1 Academic Research Institutes
14.14.2 Diagnostic Centers
14.15 Basis Point Share (BPS) Analysis by End User
14.16 Absolute $ Opportunity Assessment by End User
14.17 Market Attractiveness Analysis by End User
Chapter 15 Competition Landscape
15.1 Genomics Personalized Health Market: Competitive Dashboard
15.2 Global Genomics Personalized Health Market: Market Share Analysis, 2019
15.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
15.3.1 F. Hoffmann-La Roche AG
15.3.2 Interleukin Genetics Inc.
15.3.3 DNA Genotek Inc.
15.3.4 Genetic Technologies Limited
15.3.5 Eastern Biotech and Life Sciences
15.3.6 Biome Inc.
15.3.7 INVITAE Corporation
15.3.8 Thermo Fisher Scientific Inc.
15.3.9 QIAGEN
15.3.10 Bio-Rad Laboratories Inc.
15.3.11 XCode Life Sciences Private Limited.
15.3.12 Lonza Group
15.3.13 Illumina Inc.
Segments Covered in the Report
The global Genomics Personalized Health market has been segmented based on
By Test Type
The global Genomics Personalized Health market has been segmented based on
By Test Type
- Oncology Testing
- Orphan Disease Testing
- Autoimmune Disease Testing
- Infectious Disease Testing
- Obstetrics Testing
- Microarray
- NGS platforms
- RT-PCR
- Genetic Analyzers
- Academic Research Institutes
- Diagnostic Centers
- Asia Pacific
- North America
- Latin America
- Europe
- Middle East & Africa
- F. Hoffmann-La Roche AG
- Interleukin Genetics Inc.
- DNA Genotek Inc.
- Genetic Technologies Limited
- Eastern Biotech and Life Sciences
- Biome Inc.
- INVITAE Corporation
- Thermo Fisher Scientific Inc.
- QIAGEN
- Bio-Rad Laboratories Inc.
- XCode Life Sciences Private Limited.
- Lonza Group
- Illumina Inc.
Our Clients
Related Reports
Some other reports from this category!
